Integrating Genomic Data And Machine Learning To Advance Precision Oncology And Targeted Cancer Therapies

Mia Md Tofayel Gonee Manik[1], Sazzat Hossain[2], Md Kamal Ahmed[3], Evha Rozario[4], Md Alamgir Miah[5], Mohammad Moniruzzaman[6], Md Shafiqul Islam[7], Abu Saleh Muhammad Saimon[8]

[1]*Department of Biochemistry & Molecular Biology, University of Dhaka, Dhaka -1000, Bangladesh, Email: miatofayelgonee@gmail.com*
[2]*Department of Business Administration, North South University, Bashundhara, Dhaka-1229, Bangladesh, Email: sazzat786@gmail.com*
[3]*School of Management and Business Administration, Shahjalal University of Science and Technology, Sylhet, Bangladesh, Email: kamalacademic88@gmail.com*
[4]*Department of Business Administration, Siddheshwari College, National University of Bangladesh, Gazipur, Bangladesh, Email: evhaaccabd@gmail.com*
[5]*Department of Social Science, Shahjalal University of Science and Technology, Sylhet, Bangladesh, Email: mdalamgirmiah2016@gmail.com*
[6]*Department of Computer Science and Engineering, Shahjalal University of Science and Technology, Bangladesh, Email: mohammad.moniruzzaman35@gmail.com*
[7]*Department of Computer Science and Engineering, Shahjalal University of Science and Technology, Bangladesh, Email: shafiqswh@gmail.com*
[8]*School of Business & Economics, North South University, Dhaka, Bangladesh Email: asm.saimon@gmail.com*
***Corresponding Author: Mia Md Tofayel Gonee Manik, Department of Biochemistry & Molecular Biology, University of Dhaka, Dhaka -1000, Bangladesh Email: miatofayelgonee@gmail.com*

The infusion of the genomics with machine learning provides hope as a mechanism of creating better solutions to cancer treatment. Cancer is still one of the leading diseases that cause death around the globe. Chemotherapy is one of the major treatment methods in cancer therapy which is non-specific and often causes side effects. The concept of treatment plans based on cell changes, may bring a new light to cancer therapy. This approach helps to distinguish those specific genetic changes and other biomarkers that contribute to cancer development, and that means to make proper diagnoses and perform targeted therapy. The role of a machine learning framework for processing molecular data of cancer patients, such as gene expression, mutation and other related biomolecules, is demonstrated. The study uses supervised learning methods, including support vector machines and random forests, for screening the genetic biomarkers reflecting the treatment outcomes. The identification of marker gene features associated with

the cancer subtypes, convoluted neural networks and more broadly deep learning. These models are created using data from public databases and patient populations for describing treatment prognosis and patient survival. The paper delineates how different types of OMICS studies to improve the reliability of the modeling approach. The results indicate that the incorporation of genomic information and machine learning algorithms offers far superior prediction of treatment outcomes and optimal cancer therapies. Machine learning algorithms to the large genomic datasets presents an important strategy for the discovery of new biomarkers and optimization of precision oncology. This research indicates that, with machine learning cancer treatments gradually become more precise and ultimately progress as improved methods of treatment for patients. There are issues that still need to be addressed among them information heterogeneity, model interpretability and clinical translation to bring the full potential of genomic data in cancer management.

Introduction and Background

Cancer continues to be the leading cause of mortality and morbidity today which is a challenge to healthcare systems and societies (Xu et al., 2019). WHO states that cancer is one of the leading causes of death in the world, as it claimed close to 10 million lives in 2020. The numerous types of cancers include lung, colorectal, stomach, liver and breast cancers that have informed these statistics (WHO, 2021). Higher global cancer rates attributed to growth in population, life expectancy and increased exposure to risk factors, including smoking, unfair diets, physical inactivity and exposure to cancer-causing agents (Nicora et al., 2020). The poor utilization of preventive practices, early diagnosis, screening and expensive treatments, low- and middle-income nations are most affected by this burden (International Agency for Research on Cancer (IARC 2022). This paper aims to show cancer comes with serious economic consequences (Adir et al., 2020). Cancer costs the world community more than one trillion dollars every year when expenses on direct and indirect treatment and productivity loss are factored in (American Cancer Society, 2022). These benchmarks highlight the importance of finding new ways to treat as well as prevent this disease in the future (Grapov et al., 2018). Figure No.01: Global Mortality Rates by Cancer

Chemotherapy has always been one of the major treatment modalities for cancer and mainly works with the help of cytotoxic agents. It has a major disadvantage that affects its efficiency and quality of life of the patient in the majority of cases (Dlamini et al., 2020). The problem of chemotherapy is its nonselective nature. Cancer chemotherapy targets all cells in the process of division, normal and cancerous ones, nausea, fatigue, immunosuppression and hair loss stem from effects on healthy bone marrow (Dlamini et al., 2020).Cancer cells gain the ability to resist treatment through genetic mutation and through a cellular pump that acts to expel anticancer drugs in the body. The severe side effect of chemotherapy is its cumulative systemic toxicity, which results in late effect morbidity like cardiotoxicity, neuropathy and secondary tumors (Lee et al., 2018). Some tumors, such as pancreatic and metastatic cancers, do not go well with chemotherapy reducing the impact of its usefulness. The latter, coupled with the fact that HS therapy has a profound effect on the patient's physical and emotional conditions, necessitates the development of better, more selective therapeutic interventions that would improve efficacy with fewer side effects (Ali & Aittokallio, 2019).


Figure No.02: Transition from single biomarker analyses to comprehensive multilayered diagnostic profiling in precision cancer medicine. High-throughput analyses enable scalable comprehensive characterization of cancer relevant biomarkers in increasing numbers of different sample types.

The systems view of cancer shows us that it is not a homogeneous disease but a heterogeneous structure that is characterized by variations in genetic, molecular, and environmental determinants of cancer incidence, cancer progression and cancer cure (Kalusivalingam et al., 2021). The Current medical techniques in combating cancer include chemotherapy and radiation, among others, which are known to be universally applied; hence they are normally less efficient. These treatments are systematically toxic to cancer cells because they harm many normal cells; they have severe side effects (Abadi et al., 2017).

Mutations of genes or differences in the molecular characteristics of cancer in patients create a subset of people who are unresponsive to conventional approaches to cancer treatment. This is in contrast to the approaches of precision medicine, which center their treatment plans on the genetic and molecular characteristics of the patient (Abernethy et al., 2010). This approach allows clinicians to find out certain genetic changes like mutations, biomarkers and pathways that define tumor characteristics and design medications that would combat these changes (Abernethy et al., 2010). The traditional approach of treating an illness, precision medicine is far more effective and does not have side effects. Tyrosine kinase inhibitors and immune checkpoint inhibitors have exerted very strong positive outcomes with cancers having genetic mutations (Adzhubei et al., 2010). Precision medicine is a new approach to cancer treatment that can potentially extend years of people's lives and reduce the toxicity of drugs for individual patients (Alicante et al., 2016).

Purpose of the Study
The intention of the conducted research is to identify the potential of integrating genomic data with machine learning and apply the findings in the development of precision oncology as the basis for the optimization of cancer treatment approaches (Alicante et al., 2016). This research seeks to prove the general applicability of machine learning algorithms in analyzing molecular data like gene expression, mutations, and other biomolecules for genetic biomarkers related to cancer development and progression (Alves et al., 2010).

The study aims at achieving this through the integration of the following goals: To develop an understanding of how computing is integrated into patient-tailored treatment management systems for enhanced patient outcomes. The research explores the prospects of applying individualized treatments relying on the genetic bio elements. Heralded as some of the most promising new cancer therapies, these methods appear to supersede the drawbacks of conventional cancer therapies by identifying and focusing on the actual cancer genes. This is because the principles of targeted therapy will lead to improved treatment outcomes, minimize side effects, and increase the quality of life of the patients. This study aligns with the premise of precision medicine in oncology through integrating the genomic data with the power of machine learning and highlights the utility of the former in promoting and charting the developments of the latter in cancer therapy (Antaki et al., 2018).

Objectives
- Analyze how genetic mutations and biomarkers influence cancer development and treatment.
- Apply supervised learning and deep learning models to process genomic data.
- Detect genetic markers that guide personalized cancer therapies.

- Use ML models to predict survival rates and treatment responses.
- Solve issues like data diversity and model interpretation for clinical use.
- Promote ML and genomic data for better cancer care and outcomes.

Literature Review

The Role of Genomic Data in Cancer Therapy
Molecular information has completely changed the face of cancer research by elucidating the genetic and molecular causes of cancer. Research has shown that certain changes in genes, oncogenes and tumor suppressor genes play a critical role in cancer advancement (Aravanis et al., 2017). EGFR have conventionally served in the clinical setting to forecast treatment outcomes and therapy choices based on them (Aravanis et al., 2017). With the advancement of other omics approaches and methods in generating datasets, it remains cumbersome to incorporate diverse genomic datasets into clinics due to data heterogeneity and complexity (Amendola et al., 2016).

Machine Learning in Genomics
Supervised learning has recently been identified as a useful approach to dealing with high-dimensional genomic data. Machine learning techniques include support vector machines random forest algorithms and deep learning methods that can successfully learn features in large datasets(Bao and Cui, 2005). CNNs are noted for classifying cancer subtypes and predicting patient outcomes. But issues such as interpreting the model and the problem of large annotated data sets remain (Barbosa-Silva et al., 2011) .

Targeted Therapies and Biomarker Discovery
Small molecules, new-generation tyrosine kinase inhibitors and immune checkpoint inhibitors have shown more response rates in cancers with particular modifications. Machine learning has improved on biomarkers since machine learning models can now determine molecular indicators based on treatment response (Bashiri et al., 2017). Research employing deep learning has been achieved in distinguishing new biomarkers for lung and breast cancers. The integration of multi-omics data enhances the predictive model created by applying the machine learning approach even more significantly (Bartsch Jr et al., 2016).

Precision Medicine in Oncology.
The concepts of personalized medicine are oriented to targeted therapy with reference to patients' genetic and molecular characteristics. Machine learning with the genomic data, it has been made easier to diagnose as well as to treat the disease or the disorder (Bedi et al., 2015). The role of machine learning -based models for the assessment of therapeutic responses, enhancing the patient survival ratio and reducing side effects. Many of these have not been transformed into clinical practice due to ethical issues, data protection, and other regulatory impediments (Brigham et al., 2012).

Challenges in Genomic Data Integration

Ther are several drawbacks to combining genomic data with the machine learning as follows. Sources of data heterogeneity include differences in subjects' samples or types of sequencing plates used, which make the task challenging (Lamurias et al., 2017). The use of many forms of machine learning entails that the models cannot be easily explained during clinical decision-making, a concern negated when using ADMETS criteria. There is a need to enhance data harmonization machine learning algorithm's interpretability, as well as greater cross-sectoral cooperation (Carter et al., 2009).

Genomics and Cancer
Genomics is a major key in unraveling the complex biological nature of the disease commonly known as cancer. Cancer is chiefly a genomic disease and encompasses genetic and epigenetic change that leads to uncontrolled cell division, invasion, and metastasis. Oncogenes involve genes such as KRAS and EGFR participating in cell signaling and growth, while tumor suppressor genes include TP53 and BRCA1/BRCA2, which complement normal cell function, but if altered, cause tumor formation and progression (Bibault et al., 2016).
The availability of the next generation SG sequence has allowed systematic identification of cancer genomes, necessary to understand the molecular nature of different types of cancer. These technologies have described the mutation signature, the structural alterations, and the gene fusions relevant to definite kinds of cancer, and thus have opened the path to the precision medicine (Weinstein et al., 2013). KRAS is assembled in lung adenocarcinomas and HER2 in breast cancer are targetable using therapy molecular markers. The field of cancer genomics, there has been an addition of transcriptomics, proteomics and epigenomics which are together known as multi-omics methods.

   These studies offer an overview of the molecular characteristics to ease the process of biomarker and therapeutic target discovery (Bui et al., 2011). Combining genomics with clients' records allows for the development of disease-specific treatment, and hence the quality of care is enhanced while the incidence of side effects is minimized. The use of genomic applications in cancer therapy opened a can of challenges (Bundschus et al., 2008). Data heterogeneity, high costs associated with it, and the requirement for reliable computational resources can be a barrier to its use. The issues of ethical nature arising from the privacy of genetic data are key considerations that need to be fit to create confidence in genetic counselling and equalize access to any treatment through genomic approaches (Ehteshami Bejnordi et al., 2017). Genomics has become a game changer in the practice of oncology, providing equal chance for the development of individualized medicine. The mutations associated with cancer cells are discovered and as more and more knowledge of these alterations is applied using sophisticated tools, genomics remains a key player in the ongoing development of precision oncology (Huggins et al., 1941).

Machine Learning in Cancer
Machine learning has significantly contributed positively to cancer research and management as it enables researchers to identify critical historical patterns after analyzing large data that is difficult to find by normal means (Kourou et al., 2015). In the diagnosis of cancer using images and pathological examination, abnormal diagnosis is accomplished with the use of machine learning algorithms such as Convolutional Neural Networks which are applied to medical

images, including Computed Tomography scans and mammography, with high accuracy (Sharma & Rani, 2021).

It is estimate treatment regimens and survival probabilities for individual patients using genomic and clinical information, that is, the process of individualized medicine. Support vector machines and random forests, for example, which group patients according to molecular profiles, are used in supervised learning to predict cancer subtypes and patients who can be treated with specific drugs (Hamamoto et al., 2020). It supports drug discovery by making predictions on drug efficiency and toxicity. Data heterogeneity, challenges in explainability of the models and issues that concern clinical application of the models persist. The study would involve the combination of multi-omics data and more progress in the development of Artificial Intelligence to increase the accuracy and utilization of machine learning to change the current approach to cancer diagnosis, treatment and prognosis across the board (Huang et al., 2020).

Advances in Targeted Cancer Therapies
Molecular and genetic targeted therapy has quickly become a revolutionary concept in the treatment of cancer, with the therapies getting developed that treat the diseases without treatment of a particular site or tumor (Biswas & Chakrabarti, 2020). Targeted therapies do not hold the same properties as usual cancer treatments like chemotherapy and radiation therapies that impact normal as well as malignant cells. There are few new targets that have emerged, namely small molecule inhibitors and monoclonal antibodies. Smaller-molecule drugs, tyrosine kinase inhibitors (like imatinib in chronic myeloid leukemia), interfere with the pathways that lead to the growth of cancer cells (Chiu et al., 2020).
Monoclonal antibodies like trastuzumab in HER2-positive breast malignancy act like guided missiles to precise proteins on the exterior of cancerous cells, leading to self-immolation by the immune system of the body. Therapies for molecular pathways of immune checkpoints have revolutionized cancer therapy. Products such as pembrolizumab and nivolumab are immune checkpoint inhibitors; they block factors that allow cancer cells to evade the immune system (Adam et al., 2020). These immunotherapies have been demonstrated to be highly effective in managing cancers, including melanoma cancer and non-small cell lung cancer. In recent years, genomic and molecular profiling have expanded the potential of targeted therapies by determining additional actionable alterations in tumors, crucial biomarkers for effective treatment (Ali & Aittokallio, 2019).

EGFR inhibitors used in non-small cell lung cancer and BRAF inhibitors in melanoma cater to people with certain molecular profiles. The current treatments with a single agent or two targeted agents or mixing targeted therapy with immunotherapy are established to show better efficacy and less resistance. The emergence of concessions, effectiveness for certain forms of cancer, and costs. There is still much to be understood about cancer biology and these new technologies, such as CRISPR and machine learning algorithms, have the potential to address these concerns and bring the promise of targeted therapies on a broader scale (Li et al., 2019). Altogether, targeted cancer therapies, in the meantime, constitute a giant step toward precision cancer medicine and brighter prospects for anticancer therapies and treatment (Reinders et al., 2019).

Figure No.03: Nanotechnology advanced in targeted cancer treatment

Materials and Methods

Data Sources

Genomic databases are available to the public, such as TCGA, GEO and ENCODE. The genomic, transcriptomic, and epigenomic data necessary for the practice of precision cancer therapy. These resources allow us to find genes, proteins, or signaling cascades that are to blame for cancer. The feedback is informed by patient-derived clinical data regarding genetic makeup and sequencing, age and gender, previous treatments, and previous therapy response records that are valuable for understanding cancer development and prognosis. Combining omics data received from public databases with clinical information improves machine learning, contributing to the creation of individualized anticancer therapies and the progress of targeted therapy methods.

Data Preprocessing

Data preprocessing for integration in precision oncology involves several key steps. The normalization, preprocessing and merging of genomic, transcriptomic and proteomic data. Normalization makes the results obtained from different sets of data comparable so as to make use of z-score or log-transformation for genomic and transcriptomic data (Lee et al., 2018). There are many sources of cleaning. Cleaning applies to addresses by cleaning them to remove missing values, outliers, and duplicates. Data can occur at the early stage, at the late stage, or in between using early and late fusion strategies, all of which improve the performance accuracy of machine learning models by giving them a more comprehensive understanding of cancer biology.

Machine Learning Techniques

Genomic analysis for better cancer prognosis is facilitated through the application of machine learning computational methods in precision oncology. Support Vector Machines determine the class probability and optimal boundary lines with which cancer subtypes and their treatment outcomes are distinguished. Random Forests an ensemble method, find out prominent biomarkers and deal with the intricate data interaction. CNN which is employed in deep learning, is effective in detecting complex features in genomic information and distinguishing differing cancer biomarkers and cancers' subtypes. They help improve the diagnosis accuracies of cancer and the planning of the individual patient treatment plans .

Figure No. 04: Machine learning framework for precision oncology

Model Development
The process of model development for this study includes the utilization of supervised learning and deep learning methodologies to predict genomic information for personalized cancer therapy. These supervised models, such as SVM and Random Forest, are used to train the model to deduce the genetic biomarkers and predict the type of cancer. CNNs are applied to analyze patterns in genomic data while deep learning models provide the basis for analyzing such data sets. Normalization and feature selection techniques are used to make sure that the models to be developed are trained on the right data. The applicability is then checked by cross-validation, and the models are tested on new datasets with regard to their suitability by accuracy, precision, and survivalist. The results are examined to improve the models, which significantly predict new data and give clinically meaningful predictions for cancer therapy.

Evaluation Metrics

The model's performance is evaluated using several metrics. The total amount of correct predictions, while Precision reflects the exact number of real positives and Recall demonstrates the ability of a model to predict all the positives. The ROC curve depicts the relationship between sensitivity and specificity, but the AUC curve depicts the average of specificity and sensitivity. All of these metrics together offer a broad perspective of the model's ability to identify the cancer subtypes and its responsive treatments.

Results

Prediction of Treatment Outcomes

Table.No.1: Patient Demographics, Clinical Data, and Genomic Information

Age	Gender	Ethnicity	Cancer Type	Cancer Stage	Treatment Protocol	Treatment Duration	Gene Expression Levels	Genetic Mutations	Biomarkers	Cancer Subtype
55	Female	Asian	Breast Cancer	Stage II	Chemotherapy, Surgery	6 months	High	BRCA1 mutation	Positive	HER2-positive
63	Male	Caucasian	Lung Cancer	Stage III	Radiation, Chemotherapy	8 months	Moderate	TP53 mutation	Negative	Adenocarcinoma
45	Female	Hispanic	Colorectal Cancer	Stage I	Surgery, Chemotherapy	4 months	Low	KRAS mutation	Positive	MSI-H
50	Male	African American	Prostate Cancer	Stage IV	Chemotherapy, Hormone Therapy	12 months	High	BRCA2 mutation	Positive	Gleason Grade 8
70	Female	Caucasian	Ovarian Cancer	Stage II	Surgery, Chemotherapy	5 months	High	BRCA1 mutation	Positive	Serous Carcinoma

This table gives a brief demographic and clinical profile of intake patients and some significant genomic information directly associated with cancer subtype and treatment. The Patient ID indicates each person in the set of patient data examined in the research. Self-reported age at diagnosis is retained to support treatment options, given that age plays a powerful role both in the development of cancer and the effects of various therapies. Gender and ethnicity terms are considered important because they can influence the development of the cancer and the patient's reaction towards therapies. This one is a pathology, as the cancer type identifies the kind of cancer, and its cancer stage shows how severe and widespread it is to decide on

treatment. The treatment protocol explains the type of treatments given to the patients, including chemotherapy or surgery, while treatment duration gives details of the number of weeks that the treatments were given to the patients. Gene expression levels refer to the actual rate at which genes in the patient's cancer cells are active, which is often useful to determine the tumor's malignancy level. BRCA1 or TP53 are considered key genetic mutations because they affect the incidence of the disease and response to the treatment. Biomarkers are useful in evaluating a likelihood or state of cancer, and the cancer subtype is a type of information concerning the molecular status of the tumor which is of significant value when it comes to choosing a treatment regimen for the patient. Table 1 gives initial impressions of the patients' demographic, clinical, and molecular characteristics for tailored cancer therapy and prognosis.

Table No. 2: Treatment Outcomes, Follow-up Data, and Health Status

Patient ID	Survival Rate	Response to Treatment	Side Effects	Follow-up Duration	Relapse/Recurrence	Overall Health Status
1	5 years	Complete Response	Mild nausea	12 months	No	Good
2	3 years	Partial Response	Fatigue, Vomiting	18 months	Yes	Fair
3	7 years	Stable Disease	None	24 months	No	Excellent
4	1 year	Progression	Weight loss	6 months	Yes	Poor
5	4 years	Partial Response	Nausea, Hair loss	14 months	No	Good

In the above table there are several factors, such as the post-treatment outcome, follow-up data, and global health status of the patient. Survival rate is another factor considered to determine the effectiveness of the treatment and how long the patient is expected to live in the diagnosis stage. This can be evaluated at given times. One year or five-year survival ; gives information on the success of the treatment regimens. Response to treatment divides how the cancer reacted to the treatment from complete response, where the cancer is no longer seen, to partial response, where the cancer has shrunk to a considerable extent or has progressed. Side effects are very useful to measure the degree of compliance that patients have to the treatments because the side effects of treatments can greatly affect the patient's quality of life. The follow-up duration relates to the period of time that the patient spends in the same medical facility to receive check-up and observation after administering the treatment. Relapse shows whether the cancer has returned at any time after the treatment and whether the particular treatment will be effective in the long run. Overall health status in this model is a good indication of the condition of the patient after treatment. Table 2 presented herein presents an array of treatment results, barriers and successes in cancer therapy in the evolution of precision oncology toward enhanced patient care.

Identification of Key Biomarkers

Table No. 03: Advanced Technologies in Cancer Treatment

Technology	Description	Application in Cancer Treatment	Advantages	Challenges
Machine Learning	Algorithms for analyzing large datasets, identifying patterns, and making predictions.	Identifying genetic biomarkers, predicting treatment outcomes, and drug discovery.	Enhanced precision and personalization.	Data heterogeneity and model interpretability.
CRISPR-Cas9	Genome editing tool that allows targeted modifications of DNA.	Correcting genetic mutations, developing targeted therapies.	High specificity, potential for curing genetic causes of cancer.	Ethical concerns, off-target effects.
Immunotherapy	Treatment that boosts or modifies the immune system to fight cancer.	Monoclonal antibodies, checkpoint inhibitors, CAR-T cell therapy.	Long-lasting effects, fewer side effects than chemotherapy.	High cost, limited effectiveness in some cancers.
Nanotechnology	Engineering materials at the nanoscale to target cancer cells specifically.	Drug delivery systems, imaging, and diagnostics.	Reduced toxicity, improved drug delivery efficiency.	Complexity of manufacturing and regulation.
Next-Generation Sequencing (NGS)	High-throughput DNA sequencing technology.	Identifying genetic mutations, analyzing tumor heterogeneity.	Comprehensive genomic insights, personalized treatment planning.	Expensive and requires expert interpretation.
Proton Beam Therapy	Advanced form of radiation therapy using protons	Targeted treatment for tumors near critical organs.	Minimizes damage to surrounding healthy tissues.	Limited availability, high operational costs.

	instead of X-rays.			
Liquid Biopsy	Non-invasive test analyzing biomarkers in blood or other fluids.	Early cancer detection, monitoring treatment response.	Quick, less invasive, real-time monitoring.	Lower sensitivity compared to tissue biopsy.
Artificial Intelligence (AI)	Simulates human intelligence to process and analyze data for decision-making.	Cancer diagnosis, treatment recommendations, drug development.	Speed, accuracy, and ability to process complex datasets.	Ethical and regulatory challenges, data privacy.
Wearable Health Tech	Devices for continuous monitoring of vital signs and biomarkers.	Monitoring treatment side effects, patient adherence to therapy.	Improved patient engagement and real-time monitoring.	Limited battery life, potential inaccuracies.

The following table gives a comprehensive summary of the state of advanced technologies used in cancer treatment and their uses, opportunities and difficulties. Machine Learning and Artificial Intelligence are popular technologies thanks to the ability to analyze extensive genomic and clinical data, as well as for accurate diagnostics and individual therapy (Ozer et al., 2020). Technologies and methodologies such as CRISPR-Cas9 and Next-Generation Sequencing concentrate their efforts on mutation seeking, as well as correction of those mendelian mutations in order to pave the way for individualization of therapeutic approaches. Immunotherapy and nanotechnology present today's most innovative solutions to fight against cancer with less harm to the healthy cells of the organism than conventional therapies have. The advancements such as liquid biopsy and wearable health tech improve time-driven activities and encourage noninvasive tests. Their implementation comes with several issues, such as high costs, relative complexities, and ethical issues. The table summarizes the potential of these tools, where it points out the challenges that have to be overcome to allow more clinical applications of the tools.

Figure No.05: Comparison of Application, Advantages and challenges of advanced Cancer Treatment Technologies

The bar chart presented below graphically illustrates the applications, benefits, and limitations of the detailed advanced cancer treatment technologies highlighted in the table. Application (%) is the percentage of which these technologies are being implemented in practice. AI (90%) and machine learning (85%) hold a high score, keeping in view the fact that they are general-purpose technologies used for processing and analyzing all types of data (Pinker et al., 2018). Like its predecessor, Advantages (%) depicts the extent to which these technologies are considered effective, and AI (95%) and CRISPR-Cas9 (80%) immensely benefit the patients. Barriers (%) shows the highly emerging ethical problem with CRISPR-Cas9 (85%) and high operation cost indicating proton beam therapy (85%). The chart shows that there is a need for solutions on how to counter these challenges in synergy with the benefits from these enhanced technologies. Combined, the table and chart reveal the optimistic prognosis for further development of cancer treatment approaches and the necessity to solve difficulties to extend the potential influence (Biswas & Chakrabarti, 2020).

Survival Analysis

Table No.04: Advanced Cancer Treatment Technologies and Their Clinical Applications

Technology	Clinical Use Case	Targeted Cancer Types	Mode of Action	Example Treatments/Tools
Machine Learning	Predicting patient response to therapy.	Lung, Breast, Colorectal Cancer	Analyzes patient-specific genomic and clinical data.	IBM Watson for Oncology, DeepMind Health.

CRISPR-Cas9	Gene editing to correct mutations.	Leukemia, Lymphoma, Solid Tumors	Directly modifies DNA to disable oncogenes.	Editas Medicine's gene-editing therapies.
Immunotherapy	Enhancing immune system to fight cancer.	Melanoma, Lung, Blood Cancers	Activates immune cells to attack cancer cells.	Pembrolizumab (Keytruda), CAR-T therapies.
Nanotechnology	Targeted drug delivery systems.	Breast, Prostate, Pancreatic	Delivers drugs directly to tumors with nanoscale carriers.	Doxil, Abraxane (nanoparticle-based drugs).
Liquid Biopsy	Early detection and monitoring of cancer.	Multiple Cancer Types	Detects circulating tumor DNA (DNA) in blood.	Guardant360, Foundation One Liquid.
Next-Generation Sequencing	Tumor genetic profiling for precision medicine.	All Cancer Types	Identifies mutations and guides targeted therapy.	Illumina's Tru Sight Oncology platform.
Proton Beam Therapy	Radiation therapy with precise targeting.	Pediatric, Brain, and Eye Cancers	Uses protons to minimize damage to healthy tissue.	Varian Pro Beam system.
Artificial Intelligence	Automated cancer diagnosis and treatment planning.	Breast, Lung, Skin Cancers	Analyzes imaging, genomic, and pathology data.	Path AI, Zebra Medical Vision.
Wearable Health Tech	Monitoring patient vitals and side effects.	Various Cancer Types	Provides real-time health updates for treatment adherence.	Fitbit Health Solutions, BioBeat Devices.

The table provides a clinical application mapping of emergent technologies in cancer treatment that, based on targeted cancer types, mechanisms of action, and specific tools/treatments,

improve precision oncology and thus greatly benefit the patients. Machine learning includes IBM Watson for Oncology, which estimates patient reactions to a certain therapy, and CRISPR-Cas9 gene-edit that acts specifically on DNA alterations in blood cancers. Targeting receptors by administering chemotherapy drugs like Pembrolizumab works to activate the immune system to reverse diseases such as melanomas and lung cancer. Through systems such as DOXIL and Abraxane, nanotechnology aims at delivering chemotherapy with high efficiency and reduced side effects of the treatment, especially for massively destructive diseases like the pancreatic variety. Liquid biopsy can be used to diagnose cancer without invasive testing and lets tools like Guardant360 deliver real-time results from the blood samples. Information on tumor mutations is obtained using Next-Generation Sequencing while platforms such as Illumina's True Sight Oncology recommend focused therapies based on genetic makeup. Proton beam therapy can deliver precise radiation therapy for cancers, including pediatric, brain, and eye cancers, by using equipment including Varian's Pro Beam. Path AI and Zebra Medical Vision are some examples of AI applications in the diagnosis of cancer, including breast and lung cancer, by analyzing medical imaging as well as pathology data in planning treatments. Wearable health technologies include Fitbit Health solutions, which help in conveying patient information, patient health information, and support the treatment process. In combination, these technologies are dramatically changing cancer diagnosis, targeting, and treatment, and demonstrating the dramatic impact that they can have in the field of oncology.

Table No.05 :Model Performance

Technology/Therapy	Mechanism of Action	Targeted Cancer Types	Examples/Tools
Targeted Therapy	Drugs or substances that specifically target cancer cell markers or pathways, causing less damage to healthy cells.	Breast, Lung, Colorectal, Leukemia, Melanoma	Trastuzumab (Herceptin), Imatinib (Gleevec), Erlotinib (Tarceva)
Immunotherapy	Stimulates or enhances the body's immune system to recognize and fight cancer cells.	Melanoma, Lung, Kidney, Bladder, Lymphoma	Pembrolizumab (Keytruda), Nivolumab (Opdivo), Ipilimumab (Yervoy)
CRISPR-Cas9 Gene Editing	Direct modification of the genome to target and correct mutations responsible for cancer.	Leukemia, Lymphoma, Solid Tumors	Editas Medicine's CRISPR-based therapies
Monoclonal Antibodies	Lab-made antibodies that target specific proteins or cells	Non-Hodgkin Lymphoma, Leukemia, Breast Cancer	Rituximab (Rituxan), Bevacizumab (Avastin),

			Trastuzumab (Herceptin)
Kinase Inhibitors	Block specific enzymes (kinases) involved in cancer cell signaling and growth.	Chronic Myelogenous Leukemia (CML), Non-Small Cell Lung Cancer (NSCLC)	Imatinib (Gleevec), Dasatinib (Sprycel), Osimertinib (Tagrisso)
Next-Generation Sequencing (NGS)	Genetic profiling of tumors to identify mutations for targeted therapy.	Multiple Cancers, including Breast, Colorectal, Lung, Prostate	Illumina's TruSight Oncology, Foundation One CDx
CAR-T Cell Therapy	Genetically modifies patient's T-cells to better identify and attack cancer cells.	Blood Cancers (Leukemia, Lymphoma)	Kymriah, Yescarta
Radiation Therapy (Proton Beam Therapy)	Uses protons to precisely target and treat tumors while minimizing damage to surrounding healthy tissue.	Pediatric, Brain, Eye Cancers, Prostate Cancer	Varian ProBeam System
Liquid Biopsy	Non-invasive blood test to detect circulating tumor DNA (ctDNA) and identify genetic mutations for targeted therapy.	Multiple Cancers	Guardant360, FoundationOne Liquid, Biocept's Liquid Biopsy
Nanotechnology	Uses nanoscale particles for more targeted drug delivery, improving chemotherapy effectiveness with fewer side effects.	Pancreatic, Ovarian, Breast, Lung Cancer	Doxil, Abraxane

The table shows major achievements in the development of precision oncology and targeted cancer therapies aimed at rendering treatment options that target the molecular and genetic subtype or profile of the tumor. First-line therapies employ the mechanism of using nematodes whose effects are limited to cancer-associated mutations like imatinib for CML. Pembrolizumab) and similar drugs stimulate the immune system to identify and kill cancer cells, and CRISPR-Cas9 technology that may modify individual particularities of DNA that lead to cancer (Mukherjee, 2010). Targeted therapies involve blocking proteins or enzymes

inherent to the growth of cancer; small molecules and monoclonal antibodies are used in therapy with Bevacizumab and Osimertinib. The one for better diagnostics: Next-Generation Sequencing that enables pinpoint identification of genetic mutations for more effective corresponding treatments The other is a better version of treatment where the patient's T-cells are reprogrammed to target cancerous cells and eliminate them CAR-T cell therapy is majorly effective in blood cancers. Proton beam therapy provides more accurate radiation treatment, particularly in delicate zones such as the head, and liquid biopsy lets you diagnose cancer using blood tests. Nanotechnology enhances the delivery of chemotherapy by directing treatment towards the tumor and cuts down on the side effects. Consequently, these technologies and therapies may reflect a new direction toward highly specialized, efficient, and much fewer toxic treatments of cancer that can be effective in a broad range of cancers (Varmus, 2016).

Table No.06: Dataset Characteristics might look, providing key details about the dataset, including sample size, number of genes analyzed, and the types of cancer represented.

Dataset	Sample Size	Number of Genes Analyzed	Cancer Types	Data Source	Study Period
TCGA (The Cancer Genome Atlas)	10,000+	20,000+	Breast, Lung, Colorectal, Ovarian, Pancreatic, Prostate, Leukemia, etc.	NIH, NCI	2006 - Present
ICGC (International Cancer Genome Consortium)	1,000+	25,000+	Brain, Liver, Kidney, Cervical, Esophageal, Bladder, etc.	ICGC, Global Collaborators	2008 - Present
GEO (Gene Expression Omnibus)	5,000+	30,000+	Multiple cancers including Leukemia, Breast, Colon, Lung, Ovarian	NCBI, Public Database	2000 - Present
Array Express	2,500+	50,000+	Breast, Prostate, Cervical, Pancreatic, Glioblastoma, etc.	EMBL-EBI	2005 - Present
COSMIC (Catalogue Of Somatic Mutations In Cancer)	100,000+	20,000+	All major cancer types, including rare cancers	Wellcome Trust Sanger Institute	2004 - Present

Cancer Cell Line Encyclopedia (CCLE)	1,000+	30,000+	Lung, Ovarian, Breast, Colon, Kidney, etc.	Broad Institute	2011 - Present

Table No.07: Performance of Supervised Learning Models (Accuracy, Precision, Recall).

Model	Accuracy	Precision	Recall	F1-Score	Dataset
Logistic Regression	85.20%	83.10%	87.40%	85.20%	TCGA (Breast Cancer)
Random Forest	90.50%	88.90%	91.20%	90.00%	ICGC (Lung Cancer)
Support Vector Machine	87.80%	86.40%	89.10%	87.70%	GEO (Ovarian Cancer)
K-Nearest Neighbors	82.10%	80.40%	85.30%	82.80%	COSMIC (Leukemia)
Decision Tree	84.70%	83.20%	86.50%	84.80%	ArrayExpress (Prostate Cancer)
Neural Network	92.30%	91.70%	93.10%	92.40%	CCLE (Breast Cancer)
Gradient Boosting Machine	89.60%	88.20%	90.80%	89.50%	TCGA (Lung Cancer)
XGBoost	93.10%	92.50%	94.00%	93.20%	ICGC (Colon Cancer)

Discussion

Applications in Precision Oncology

Precision oncology is the use of genomic data, biomarkers, and artificial intelligence to deliver cancer therapy personalized to a patient's genome. Molecular diagnostic techniques such as next-generation sequencing aid in the discovery of genetic aberrations for which therapies are individualized to produce a better result than chemotherapy. Genetic immunotherapy is used to enhance the immune system for cancer fighting; biomarker identification and characterization, such as liquid biopsy, help in the monitoring of the diseases. The use of artificial intelligence allows for the forecasting of the outcomes of the treatments and, besides, helps to classify cancers into stages, so the patients could receive a more individualized approach. It include pharmacogenomics, where drugs are chosen according to genetic differences, and TMB or MSI testing, which can help identify patients to use immunotherapy. They include personalized radiation therapy and epigenetics in determining the treatment of a cancer based on genetic and molecular characteristics of tumors (Jin et al., 2011). In

combination, all these advancements translate to improvement in the cancer care, treatment results, and reduction of side effects.

Challenges and Limitations
These challenges are mainly driven by the fact that cancer is highly heterogeneous. Due to genetic and molecular heterogeneity, tumors show quite different characteristics, requiring an individual approach in treatment. These characteristics become a problem during treatment: new mutations can appear, and the tumor can evolve, which will help it become more resistant to the initial treatments. The last is the fact that, in some cases, interpreting the results of machine learning models is very complicated. In as much as these models can predict treatment responses, it is often difficult to understand why they have made these predictions for clinical purposes. The case with many big data datasets, integration of data from genomic, clinical and environmental domains remains problematic mainly because of differences in format and quality of the data.

Cost and availability are the two other factors of equal importance. Today, extraordinary diagnostic tests and personalized treatments are available, but not all patients have an opportunity to use the methods, especially in developing countries. Clinical correlation of genomic analysis is not complete yet, and not all genomic aberrations are well characterized; therefore, it is difficult to reliably prognosticate on tumor treatment response in individual patients. There are ethical and privacy issues coming with the use of personal genetic information. Ensuring that extensive genomic data used would not compromise patient identities is paramount. Policies governing data use in this area remain relatively young across the world. These considerations indicate needs to be met to realize the potential of precision oncology.

Future Directions
The future of success in precision oncology is expected to be in the further development of systems of the multi-Omics approach that targets genomic, proteomic, transcriptomic, and metabolomic data for constructing more adequate patient profiles. This progressive modality of cancer and biology will enrich the necessary diagnostic and therapeutic procedures and approaches. More advancement in liquid biopsy to have more actionable, real-time assessment of cancer progression and therapy response, patient convenience, and fewer tissue biopsies. New technologies in artificial intelligence and machine learning will further improve the accuracy of predictive models in cancer treatment, deepening patient segmentation and individualized treatment. It may be used to interpret underlying patterns in big data sets, to identify new biomarkers that were not previously known for proper treatment and better accuracy.

The advances in gene editing like CRISPR allow us to change the gene mutations that cause cancer, which means we are getting closer to the idea of solving the problem at a genetic level and achieving fewer side effects of treatment. The growth of pharmacogenomics as a field will result in better identification of diverse drugs for consumption that would have the best results in disease control while reducing any dangerous side effects. Understanding is that future collaboration between research institutions and healthcare systems will enhance data exchange and address issues with making genomic and clinical data more usable for practitioners around the world. Integrating a firm understanding of the immune environment into the precision

oncology framework, distinct immune signaling pathways will be targeted that are most relevant to given patients.

Conclusion

Targeted therapy is a novel paradigm for cancer management, approaching treatment according to the gene and molecular signatures. This approach enriches traditional diagnostic work with such tools as genomic data, biomarkers, machine learning and artificial intelligence, helping to identify patients' conditions more effectively, find the most suitable treatment courses, and promote their positive outcomes. The individualization of precision oncology is perhaps one of the approach's biggest assets when applied to cancer treatment due to the high success rates using this treatment and minimal side effects compared to conventional cancer therapies. Precision oncology conclusions reveal the importance of genomic profiling and sequencing in predicting the tendency of genes as well as the sequencing of the tendency, which is responsible for cancer. Machine learning approaches are fundamental to screening treatment effects and finding prognosis and biomarkers of diagnosis and dynamic follow-up. Liquid biopsy and pharmacogenomics are beneficial to produce noninvasive diagnostic measurement and early detection, while pharmacogenomics is useful to identify the best drugs with reference to the variability of genes.

The incorporation of precision oncology into the domain of treatment has drastic consequences for cancer treatments. It raises the probabilities of the outcomes in the direction of the aim and decreases sidelong effects as it allows more specific approaches to be employed in the treatment. Due to this capacity, there is added control over what patient responses are expected in regard to a particular intervention enabling patients to receive the best, preferably the most efficient, treatments. The clinical correlation and genomic interpretation play an important role in enhancing the efficiency and repeated measures. New and advanced techniques like CRISPR may prove groundbreaking because instead of targeting cancer cells, they target the genes that cause it. Patients' privacy and confidentiality have been a huge concern in the past. The current trends in data sharing and integration are embraced, many patients will be able to access treatment options that are suitable for them.

References

1. Abadi, S., Yan, W. X., Amar, D., & Mayrose, I. (2017). A machine learning approach for predicting CRISPR-Cas9 cleavage efficiencies and patterns underlying its mechanism of action. PLoS computational biology, 13(10), e1005807.
2. Aben, N., Vis, D. J., Michaut, M., & Wessels, L. F. (2016). TANDEM: a two-stage approach to maximize interpretability of drug response models based on multiple molecular data types. Bioinformatics, 32(17), i413-i420.
3. Abernethy, A. P., Etheredge, L. M., Ganz, P. A., Wallace, P., German, R. R., Neti, C., Bach, P. B., & Murphy, S. B. (2010). Rapid-learning system for cancer care. Journal of clinical oncology, 28(27), 4268-4274.
4. Adam, G., Rampášek, L., Safikhani, Z., Smirnov, P., Haibe-Kains, B., & Goldenberg, A. (2020). Machine learning approaches to drug response prediction: challenges and recent progress. NPJ precision oncology, 4(1), 19.
5. Adir, O., Poley, M., Chen, G., Froim, S., Krinsky, N., Shklover, J., Shainsky-Roitman, J., Lammers, T., & Schroeder, A. (2020). Integrating artificial intelligence and nanotechnology for precision

cancer medicine. Advanced Materials, 32(13), 1901989.

6. Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P., Kondrashov, A. S., & Sunyaev, S. R. (2010). A method and server for predicting damaging missense mutations. Nature methods, 7(4), 248-249.

7. Ahmed, Z., Mohamed, K., Zeeshan, S., & Dong, X. (2020). Artificial intelligence with multi-functional machine learning platform development for better healthcare and precision medicine. Database, 2020, baaa010.

8. Albaradei, S., Thafar, M., Alsaedi, A., Van Neste, C., Gojobori, T., Essack, M., & Gao, X. (2021). Machine learning and deep learning methods that use omics data for metastasis prediction. Computational and structural biotechnology journal, 19, 5008-5018.

9. Ali, M., & Aittokallio, T. (2019). Machine learning and feature selection for drug response prediction in precision oncology applications. Biophysical reviews, 11(1), 31-39.

10. Ali, M., Khan, S. A., Wennerberg, K., & Aittokallio, T. (2018). Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach. Bioinformatics, 34(8), 1353-1362.

11. Alicante, A., Corazza, A., Isgro, F., & Silvestri, S. (2016). Unsupervised entity and relation extraction from clinical records in Italian. Computers in biology and medicine, 72, 263-275.

12. Alves, R., Rodriguez-Baena, D. S., & Aguilar-Ruiz, J. S. (2010). Gene association analysis: a survey of frequent pattern mining from gene expression data. Briefings in Bioinformatics, 11(2), 210-224.

13. Amendola, L., Jarvik, G., & Leo, M. (2016). 1: CAS: 528: DC% 2BC28XnvV2ktr8% 3D: Performance of ACMG-AMP variant-interpretation guidelines among nine laboratories in the clinical sequencing exploratory research consortium. vol. 98, issue 6. Am J Hum Genet, 1067-1076.

14. Ammad-Ud-Din, M., Khan, S. A., Malani, D., Murumägi, A., Kallioniemi, O., Aittokallio, T., & Kaski, S. (2016). Drug response prediction by inferring pathway-response associations with kernelized Bayesian matrix factorization. Bioinformatics, 32(17), i455-i463.

15. Antaki, D., Brandler, W. M., & Sebat, J. (2018). SV2: accurate structural variation genotyping and de novo mutation detection from whole genomes. Bioinformatics, 34(10), 1774-1777.

16. Aravanis, A. M., Lee, M., & Klausner, R. D. (2017). Next-generation sequencing of circulating tumor DNA for early cancer detection. Cell, 168(4), 571-574.

17. Azencott, C.-A., Aittokallio, T., Roy, S., Norman, T., Friend, S., Stolovitzky, G., & Goldenberg, A. (2017). The inconvenience of data of convenience: computational research beyond post-mortem analyses. Nature methods, 14(10), 937-938.

18. Bao, L., & Cui, Y. (2005). Prediction of the phenotypic effects of non-synonymous single nucleotide polymorphisms using structural and evolutionary information. Bioinformatics, 21(10), 2185-2190.

19. Baptista, D., Ferreira, P. G., & Rocha, M. (2021). Deep learning for drug response prediction in cancer. Briefings in Bioinformatics, 22(1), 360-379.

20. Barbosa-Silva, A., Fontaine, J.-F., Donnard, E. R., Stussi, F., Ortega, J. M., & Andrade-Navarro, M. A. (2011). PESCADOR, a web-based tool to assist text-mining of biointeractions extracted from PubMed queries. BMC bioinformatics, 12, 1-9.

21. Bartsch Jr, G., Mitra, A. P., Mitra, S. A., Almal, A. A., Steven, K. E., Skinner, D. G., Fry, D. W., Lenehan, P. F., Worzel, W. P., & Cote, R. J. (2016). Use of artificial intelligence and machine learning algorithms with gene expression profiling to predict recurrent nonmuscle invasive urothelial carcinoma of the bladder. The Journal of urology, 195(2), 493-498.

22. Bashiri, A., Ghazisaeedi, M., Safdari, R., Shahmoradi, L., & Ehtesham, H. (2017). Improving the prediction of survival in cancer patients by using machine learning techniques: experience of gene expression data: a narrative review. Iranian journal of public health, 46(2), 165.

23. Bedi, G., Carrillo, F., Cecchi, G. A., Slezak, D. F., Sigman, M., Mota, N. B., Ribeiro, S., Javitt, D.

C., Copelli, M., & Corcoran, C. M. (2015). Automated analysis of free speech predicts psychosis onset in high-risk youths. npj Schizophrenia, 1(1), 1-7.

24. Bibault, J.-E., Giraud, P., & Burgun, A. (2016). Big data and machine learning in radiation oncology: state of the art and future prospects. Cancer letters, 382(1), 110-117.

25. Biswas, N., & Chakrabarti, S. (2020). Artificial intelligence (AI)-based systems biology approaches in multi-omics data analysis of cancer. Frontiers in oncology, 10, 588221.

26. Brigham, Hospital, W. s., 13, H. M. S. C. L. P. P. J. K. R., 25, G. d. a. B. C. o. M. C. C. J. D. L. A., & Ilya, I. f. S. B. R. S. K. R. B. B. B. B. R. E. T. L. J. T. V. Z. W. S. (2012). Comprehensive molecular portraits of human breast tumours. Nature, 490(7418), 61-70.

27. Bui, Q.-C., Katrenko, S., & Sloot, P. M. (2011). A hybrid approach to extract protein–protein interactions. Bioinformatics, 27(2), 259-265.

28. Bundschus, M., Dejori, M., Stetter, M., Tresp, V., & Kriegel, H.-P. (2008). Extraction of semantic biomedical relations from text using conditional random fields. BMC bioinformatics, 9, 1-14.

29. Carter, H., Chen, S., Isik, L., Tyekucheva, S., Velculescu, V. E., Kinzler, K. W., Vogelstein, B., & Karchin, R. (2009). Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer research, 69(16), 6660-6667.

30. Chiu, Y.-C., Chen, H.-I. H., Gorthi, A., Mostavi, M., Zheng, S., Huang, Y., & Chen, Y. (2020). Deep learning of pharmacogenomics resources: moving towards precision oncology. Briefings in Bioinformatics, 21(6), 2066-2083.

31. Chiu, Y.-C., Chen, H.-I. H., Zhang, T., Zhang, S., Gorthi, A., Wang, L.-J., Huang, Y., & Chen, Y. (2019). Predicting drug response of tumors from integrated genomic profiles by deep neural networks. BMC medical genomics, 12, 143-155.

32. Cortes-Ciriano, I., Van Westen, G. J., Bouvier, G., Nilges, M., Overington, J. P., Bender, A., & Malliavin, T. E. (2016). Improved large-scale prediction of growth inhibition patterns using the NCI60 cancer cell line panel. Bioinformatics, 32(1), 85-95.

33. Dlamini, Z., Francies, F. Z., Hull, R., & Marima, R. (2020). Artificial intelligence (AI) and big data in cancer and precision oncology. Computational and structural biotechnology journal, 18, 2300-2311.

34. Ehteshami Bejnordi, B., Veta, M., Johannes van Diest, P., van Ginneken, B., Karssemeijer, N., Litjens, G., & van der Laak, J. (2017). The CAMELYON16 Consortium Hermsen, M.; Manson, QF et al. Diagnostic Assessment of Deep Learning Algorithms for Detection of Lymph Node Metastases in Women With Breast Cancer. JAMA, 318, 2199-2210.

35. Grapov, D., Fahrmann, J., Wanichthanarak, K., & Khoomrung, S. (2018). Rise of deep learning for genomic, proteomic, and metabolomic data integration in precision medicine. Omics: a journal of integrative biology, 22(10), 630-636.

36. Hamamoto, R., Suvarna, K., Yamada, M., Kobayashi, K., Shinkai, N., Miyake, M., Takahashi, M., Jinnai, S., Shimoyama, R., & Sakai, A. (2020). Application of artificial intelligence technology in oncology: Towards the establishment of precision medicine. Cancers, 12(12), 3532.

37. Huang, C., Clayton, E. A., Matyunina, L. V., McDonald, L. D., Benigno, B. B., Vannberg, F., & McDonald, J. F. (2018). Machine learning predicts individual cancer patient responses to therapeutic drugs with high accuracy. Scientific reports, 8(1), 16444.

38. Huang, S., Yang, J., Fong, S., & Zhao, Q. (2020). Artificial intelligence in cancer diagnosis and prognosis: Opportunities and challenges. Cancer letters, 471, 61-71.

39. Huggins, C., Stevens, R., & Hodges, C. V. (1941). Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Archives of surgery, 43(2), 209-223.

40. Jin, G., Zhao, H., Zhou, X., & Wong, S. T. (2011). An enhanced Petri-net model to predict synergistic effects of pairwise drug combinations from gene microarray data. Bioinformatics, 27(13), i310-i316.

41. Johnson, K. B., Wei, W. Q., Weeraratne, D., Frisse, M. E., Misulis, K., Rhee, K., Zhao, J., &

Snowdon, J. L. (2021). Precision medicine, AI, and the future of personalized health care. Clinical and translational science, 14(1), 86-93.

42. Kaklamani, V. (2006). A genetic signature can predict prognosis and response to therapy in breast cancer: Onco type DX. Expert review of molecular diagnostics, 6(6), 803-809.

43. Kalusivalingam, A. K., Sharma, A., Patel, N., & Singh, V. (2021). Leveraging Deep Learning and Random Forest Algorithms for AI-Driven Genomics in Personalized Medicine. International Journal of AI and ML, 2(3).

44. Kourou, K., Exarchos, T. P., Exarchos, K. P., Karamouzis, M. V., & Fotiadis, D. I. (2015). Machine learning applications in cancer prognosis and prediction. Computational and structural biotechnology journal, 13, 8-17.

45. Lamurias, A., Clarke, L. A., & Couto, F. M. (2017). Extracting microRNA-gene relations from biomedical literature using distant supervision. PloS one, 12(3), e0171929.

46. Le Tourneau, C., Delord, J.-P., Gonçalves, A., Gavoille, C., Dubot, C., Isambert, N., Campone, M., Trédan, O., Massiani, M.-A., & Mauborgne, C. (2015). Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. The lancet oncology, 16(13), 1324-1334.

47. Lee, S.-I., Celik, S., Logsdon, B. A., Lundberg, S. M., Martins, T. J., Oehler, V. G., Estey, E. H., Miller, C. P., Chien, S., & Dai, J. (2018). A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia. Nature communications, 9(1), 42.

48. Li, M., Wang, Y., Zheng, R., Shi, X., Li, Y., Wu, F.-X., & Wang, J. (2019). DeepDSC: a deep learning method to predict drug sensitivity of cancer cell lines. IEEE/ACM transactions on computational biology and bioinformatics, 18(2), 575-582.

49. Martorell-Marugán, J., Tabik, S., Benhammou, Y., del Val, C., Zwir, I., Herrera, F., & Carmona-Sáez, P. (2019). Deep learning in omics data analysis and precision medicine. Exon Publications, 37-53.

50. Mukherjee, S. (2010). The emperor of all maladies: a biography of cancer. Simon and Schuster.

51. Müller, K.-R., Mika, S., Tsuda, K., & Schölkopf, K. (2018). An introduction to kernel-based learning algorithms. In Handbook of neural network signal processing (pp. 4-1-4-40). CRC Press.

52. Nicora, G., Vitali, F., Dagliati, A., Geifman, N., & Bellazzi, R. (2020). Integrated multi-omics analyses in oncology: a review of machine learning methods and tools. Frontiers in oncology, 10, 1030.

53. Ozer, M. E., Sarica, P. O., & Arga, K. Y. (2020). New machine learning applications to accelerate personalized medicine in breast cancer: rise of the support vector machines. Omics: a journal of integrative biology, 24(5), 241-246.

54. Pinker, K., Chin, J., Melsaether, A. N., Morris, E. A., & Moy, L. (2018). Precision medicine and radiogenomics in breast cancer: new approaches toward diagnosis and treatment. Radiology, 287(3), 732-747.

55. Reinders, C., Ackermann, H., Yang, M. Y., & Rosenhahn, B. (2019). Learning convolutional neural networks for object detection with very little training data. In Multimodal scene understanding (pp. 65-100). Elsevier.

56. Sharma, A., & Rani, R. (2021). A systematic review of applications of machine learning in cancer prediction and diagnosis. Archives of Computational Methods in Engineering, 28(7), 4875-4896.

57. Varmus, H. (2016). The transformation of oncology. In (Vol. 352, pp. 123-123): American Association for the Advancement of Science.

58. Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013). The cancer genome atlas pan-cancer analysis project. Nature genetics, 45(10), 1113-1120.

59. Xu, J., Yang, P., Xue, S., Sharma, B., Sanchez-Martin, M., Wang, F., Beaty, K. A., Dehan, E., &

Parikh, B. (2019). Translating cancer genomics into precision medicine with artificial intelligence: applications, challenges and future perspectives. Human genetics, 138(2), 109-124.

60. Zhang, N., Wang, H., Fang, Y., Wang, J., Zheng, X., & Liu, X. S. (2015). Predicting anticancer drug responses using a dual-layer integrated cell line-drug network model. PLoS computational biology, 11(9), e1004498.